NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts have a consensus rating of "Moderate Buy" on NRx Pharmaceuticals (6 firms: 4 buy, 1 hold, 1 sell) with an average one-year price target of $38.25.
• Several institutional investors have increased positions (notably Anson Funds now owns 3,043,957 shares valued at about $8.25M), and institutions collectively own roughly 4.27% of the company.
• Shares trade near $3.05 with a market cap of about $100.9M and a 52-week range of $1.62–$3.84; the latest quarter showed an EPS surprise of $0.19 vs. -$0.09 consensus while revenue was $0.98M versus $7.53M expected.

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $38.25.

Several research firms have recently weighed in on NRXP. Ascendiant Capital Markets boosted their price objective on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a "buy" rating in a research note on Monday, April 27th. D. Boral Capital restated a "buy" rating and set a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday. Zacks Research upgraded shares of NRx Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Monday, March 2nd. HC Wainwright reiterated a "buy" rating and issued a $45.00 price target on shares of NRx Pharmaceuticals in a research note on Monday, April 27th. Finally, BTIG Research reiterated a "buy" rating and issued a $25.00 price target on shares of NRx Pharmaceuticals in a research note on Tuesday, March 24th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Anson Funds Management LP grew its stake in NRx Pharmaceuticals by 50.3% in the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company's stock valued at $8,249,000 after buying an additional 1,018,853 shares during the last quarter. Vanguard Group Inc. grew its position in shares of NRx Pharmaceuticals by 18.3% during the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company's stock worth $1,765,000 after purchasing an additional 82,781 shares in the last quarter. AdvisorShares Investments LLC grew its position in shares of NRx Pharmaceuticals by 28.2% during the 1st quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company's stock worth $896,000 after purchasing an additional 92,463 shares in the last quarter. Commonwealth Equity Services LLC acquired a new position in shares of NRx Pharmaceuticals during the 4th quarter worth approximately $994,000. Finally, Geode Capital Management LLC grew its position in shares of NRx Pharmaceuticals by 17.8% during the 4th quarter. Geode Capital Management LLC now owns 218,866 shares of the company's stock worth $593,000 after purchasing an additional 33,004 shares in the last quarter. Institutional investors and hedge funds own 4.27% of the company's stock.

NRx Pharmaceuticals Price Performance

NRx Pharmaceuticals stock opened at $3.05 on Thursday. The firm has a market capitalization of $100.86 million, a PE ratio of -2.19 and a beta of 2.02. The company's 50-day moving average is $2.27 and its 200-day moving average is $2.32. NRx Pharmaceuticals has a fifty-two week low of $1.62 and a fifty-two week high of $3.84.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last released its quarterly earnings data on Monday, March 23rd. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.28. The firm had revenue of $0.98 million for the quarter, compared to analyst estimates of $7.53 million. As a group, analysts expect that NRx Pharmaceuticals will post 0.13 EPS for the current year.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company's research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx's pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.